نتائج البحث 381-390 من 6781 لعملية البحث عن immunosuppressant drugs
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
To describe the clinical, laboratory, pathologic, imaging findings, therapy and outcomes in all patients with Fibromuscular Dysplasia (FMD) and/or segmental ...
Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as ...
The median survival of patients with LM with treatment is generally less than 5 months. There are four FDA-approved drugs for intra-CSF use in LM, but all have ...
The purpose of this study is to evaluate whether profiling aggressive tumors for molecular alterations, together with drug testing in patient-derived 3D ...
Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncology. 2017; doi:10.1001/jamaoncol.2017.0424. Precision medicine ...
... drugs are safe for people to take. We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib ...
Some patients have almost no discomfort while others require significant amounts of oral narcotics and report pain of 10 out of 10 on a numerical rating scale.
Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...
... drugs in the iPSC-derived muscle cells. Mayo Clinic Vestibular Schwannoma Quality of Life Index Assessment. Rochester, Minn. The purpose of the study is to ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.